EX-99.1 2 brhc10024121_ex99-1.htm PRESS RELEASE DATED MAY 5, 2021

Exhibit 99.1


FOR IMMEDIATE RELEASE

NU SKIN ENTERPRISES REPORTS RECORD FIRST-QUARTER 2021 RESULTS

Company announces first-quarter revenue growth of 31% and EPS growth of 153%,
raises annual guidance

PROVO, Utah — May 5, 2021 — Nu Skin Enterprises, Inc. (NYSE: NUS) today announced record first-quarter 2021 revenue and earnings per share.

Executive Summary
Q1 2021 vs. Prior-year Quarter

Revenue:
$677.0 million; +31%
      +6% fx impact or $29.6 million
Earnings Per Share (EPS):
$0.91; +153%
Sales Leaders:
60,619; +22%
Customers:
1,517,260; +34%

“We are very pleased with a strong start to 2021 with our highest-ever first quarter revenue and earnings per share,” said Ritch Wood, chief executive officer. “Our innovative beauty and wellness product initiatives powered by our social commerce business model led to 34 percent growth in our customer base over the prior year and a 22 percent increase in global sales leaders. We were recognized again by Euromonitor as the world’s number one beauty device systems brand.* We continue to improve our geographic balance, driven by ongoing strong performance in the West, providing a more diversified and sustainable growth profile. Our manufacturing segment also achieved record results with 69 percent year-over-year revenue growth.”

Ryan Napierski, president and CEO-elect, added, “We continue to make progress toward our vision of becoming the world’s leading beauty and wellness company powered by our dynamic affiliate opportunity platform. We added innovative products to our portfolio with the launch of ageLOC Boost and Nutricentials Bioadaptives, and our markets are forecasting strong demand for new product innovations being introduced in the back half of the year. These include Beauty Focus Collagen+, which is the first product in a new beauty-from-within line, and ageLOC Meta, a metabolic health supplement and our next major Pharmanex product introduction. The West markets continue to lead out in adopting our social commerce business model with triple-digit growth. Our affiliates are leveraging this model to connect with more consumers and attract people interested in building their own socially enabled affiliate marketing business. In the East, we grew 14 percent in Japan and modestly in Mainland China and anticipate increased adoption of our social commerce strategy and digital tools.”


Nu Skin Enterprises Reports Record First-quarter 2021 Results 
Page 2

Q1 2021 Year-over-year Operating Results

Revenue:
$677.0 million compared to $518.0 million
      +6% fx impact
Gross Margin:
74.8% compared to 75.7%
      Nu Skin business was 77.8% compared to 78.1%
      Impacted by growth in manufacturing segment
Selling Expenses:
40.4% compared to 39.8%
      Nu Skin business was 43.4% compared to 42.0%
G&A Expenses:
25.1% compared to 28.9%
Operating Margin:
9.3% compared to 7.1%
Other Income / (Expense):
$1.6 million compared to ($6.2) million
Income Tax Rate:
26.5% compared to 35.1%
      Benefited by geographic mix
EPS:
$0.91 compared to $0.36

Stockholder Value
Dividend Payments:
$19.3 million
Stock Repurchases:
$50.4 million
      $275.4 million remaining in authorization

Q2 and Full-year 2021 Outlook

Q2 2021 Revenue:
$680 to $705 million; +11 to 15%
      Approximately +5% fx impact
Q2 2021 EPS:
$0.97 to $1.07; +20 to 32%
2021 Revenue:
$2.80 to $2.87 billion; +9 to 11%
      Approximately +3 to 4% fx impact
2021 EPS:
$4.05 to $4.30; +12 to 18%

- more -

Nu Skin Enterprises Reports Record First-quarter 2021 Results 
Page 3
 
Mark Lawrence, chief financial officer, added, “During the quarter, we continued our focus on generating shareholder value by improving operating margin through G&A optimization and leveraging our balance sheet to repurchase nearly one million shares. We continue to create synergistic value from our Rhyz manufacturing companies as they enabled the accelerated growth throughout the West. Given the strong start to the year, as well as the positive trends we have seen in customer and sales leader growth, we are increasing our annual revenue and EPS guidance.”
 
About Nu Skin Enterprises, Inc.
Founded more than 35 years ago, Nu Skin Enterprises, Inc. (NSE) empowers innovative companies with sustainable solutions, opportunities, technologies and life-improving values. The company currently focuses its efforts around innovative consumer products, product manufacturing and controlled environment agriculture technology. The NSE family of companies includes Nu Skin, which develops and distributes a comprehensive line of premium-quality beauty and wellness solutions through a global network of sales leaders in Asia, the Americas, Europe, Africa and the Pacific; and Rhyz, our strategic investment arm that includes a collection of sustainable manufacturing and technology innovation companies. Nu Skin Enterprises is traded on the New York Stock Exchange under the symbol “NUS.” More information is available at nuskinenterprises.com.
 
* Source Euromonitor International Limited; Retail Value RSP terms; all channels; 2017 to 2020. Beauty Systems are at-home Skin Care Beauty Devices that are exclusively paired or recommended to be used with a topical consumable of the same brand. Claim verification based on Euromonitor custom research and methodology conducted January-March of 2021. Sales of at-home skin care beauty devices includes sales of electric facial cleansers as defined in Passport database. This category does not include hair care/removal appliances, body shavers, and oral care appliances.

Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company’s current expectations and beliefs. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws and include, but are not limited to, statements of management’s expectations regarding the company’s performance, growth, product pipeline and product introductions, customers and sales leaders, affiliates, strategies and initiatives; projections regarding revenue, earnings per share, foreign currency fluctuations and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as “believe,” “expect,” “anticipate,” “project,” “outlook,” “guidance,” “plan,” “forecast,” “expand,” “will,” “would,” “could,” “may,” “might,” the negative of these words and other similar words.

The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:


risk that epidemics, including the ongoing COVID-19 pandemic, and other crises could negatively impact our business;
 
- more -

Nu Skin Enterprises Reports Record First-quarter 2021 Results 
Page 4
 

adverse publicity related to the company’s business, products, industry or any legal actions or complaints by the company’s sales force or others;

risk that direct selling laws and regulations in any of the company’s markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to the company’s business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, imposition of fines, or any other adverse actions or events;

any failure of current or planned initiatives or products to generate interest among the company’s sales force and customers and generate sponsoring and selling activities on a sustained basis;

political, legal, tax and regulatory uncertainties associated with operating in international markets, including Mainland China;

uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business operations and results;

risk of foreign-currency fluctuations and the currency translation impact on the company’s business associated with these fluctuations;

uncertainties regarding the future financial performance of the businesses the company has acquired;

risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies;

regulatory risks associated with the company’s products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements;

unpredictable economic conditions and events globally, including trade policies and tariffs;

the company’s future tax-planning initiatives; any prospective or retrospective increases in duties on the company’s products imported into the company’s markets outside of the United States; and any adverse results of tax audits or unfavorable changes to tax laws in the company’s various markets; and

continued competitive pressures in the company’s markets.
 
The company’s financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company’s beliefs as of the date that such information was first provided, and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.

Non-GAAP Financial Measures: Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company’s performance. It is calculated by translating the current period’s revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period’s revenue. The company believes that constant-currency revenue change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company’s revenue from period to period.

- more -

Nu Skin Enterprises Reports Record First-quarter 2021 Results 
Page 5
 
The Company’s revenue results by segment for the three-month periods ended March 31 are presented in the following table (in thousands).

   
Three Months Ended
March 31,
         
Constant-
Currency
 
   
2021
   
2020
   
Change
   
Change
 
Nu Skin
                       
Mainland China
 
$
149,593
   
$
137,696
     
9
%
   
1
%
Americas/Pacific
   
149,465
     
74,573
     
100
%
   
97
%
South Korea
   
81,131
     
75,719
     
7
%
   
 
EMEA
   
76,180
     
35,403
     
115
%
   
98
%
Japan
   
69,864
     
61,300
     
14
%
   
11
%
Southeast Asia
   
67,585
     
69,586
     
(3
)%
   
(5
)%
Hong Kong/Taiwan
   
36,345
     
35,827
     
1
%
   
(3
)%
Other
   
705
     
773
     
(9
)%
   
(9
)%
Total Nu Skin
   
630,868
     
490,877
     
29
%
   
22
%
Manufacturing
   
45,985
     
27,147
     
69
%
   
69
%
Grow Tech
   
173
     
4
     
4,225
%
   
4,225
%
Total
 
$
677,026
   
$
518,028
     
31
%
   
25
%

The company’s Customers and Sales Leaders statistics by segment as of March 31, 2021 and 2020 are presented in the following table:

   
As of
March 31, 2021
   
As of
March 31, 2020
   
% Increase (Decrease)
 
   
Customers
   
Sales Leaders
   
Customers
   
Sales Leaders
   
Customers
   
Sales Leaders
 
Mainland China
   
316,000
     
16,716
     
271,536
     
16,159
     
16
%
   
3
%
Americas/Pacific
   
407,413
     
12,340
     
214,139
     
6,930
     
90
%
   
78
%
South Korea
   
152,390
     
7,099
     
174,004
     
6,608
     
(12
)%
   
7
%
EMEA
   
296,001
     
7,950
     
140,344
     
4,237
     
111
%
   
88
%
Japan
   
126,525
     
6,131
     
119,784
     
5,635
     
6
%
   
9
%
Southeast Asia
   
152,889
     
6,882
     
145,116
     
6,634
     
5
%
   
4
%
Hong Kong/Taiwan
   
66,042
     
3,501
     
66,024
     
3,348
     
     
5
%
Total
   
1,517,260
     
60,619
     
1,130,947
     
49,551
     
34
%
   
22
%

“Customers” are persons who purchased products directly from the company during the previous three months. Our Customer numbers do not include consumers who purchase products directly from members of our sales force.

“Sales Leaders” are independent distributors, and sales employees and independent marketers in China, who achieve certain qualification requirements.

- more -

Nu Skin Enterprises Reports Record First-quarter 2021 Results 
Page 6
 
NU SKIN ENTERPRISES, INC.
Consolidated Statements of Income (Unaudited)
(U.S. dollars in thousands, except per share amounts)

   
Three Months Ended
March 31,
 
   
2021
   
2020
 
             
Revenue
 
$
677,026
   
$
518,028
 
Cost of sales
   
170,566
     
125,793
 
Gross profit
   
506,460
     
392,235
 
                 
Operating expenses:
               
Selling expenses
   
273,746
     
206,042
 
General and administrative expenses
   
169,801
     
149,628
 
Total operating expenses
   
443,547
     
355,670
 
                 
Operating income
   
62,913
     
36,565
 
Other income (expense), net
   
1,582
     
(6,174
)
                 
Income before provision for income taxes
   
64,495
     
30,391
 
Provision for income taxes
   
17,065
     
10,661
 
                 
Net income
 
$
47,430
   
$
19,730
 
                 
Net income per share:
               
Basic
 
$
0.94
   
$
0.36
 
Diluted
 
$
0.91
   
$
0.36
 
                 
Weighted-average common shares outstanding (000s):
               
Basic
   
50,706
     
55,059
 
Diluted
   
52,172
     
55,101
 

- more -

NU SKIN ENTERPRISES, INC.
Consolidated Balance Sheets (Unaudited)
(U.S. dollars in thousands)
 
   
March 31,
2021
   
December 31, 2020
 
ASSETS
           
Current assets:
           
Cash and cash equivalents
 
$
339,099
   
$
402,683
 
Current investments
   
23,615
     
21,216
 
Accounts receivable, net
   
60,625
     
63,370
 
Inventories, net
   
363,431
     
314,366
 
Prepaid expenses and other
   
114,118
     
101,563
 
Total current assets
   
900,888
     
903,198
 
                 
Property and equipment, net
   
464,247
     
468,181
 
Operating lease right-of-use assets
   
147,129
     
155,104
 
Goodwill
   
202,979
     
202,979
 
Other intangible assets, net
   
87,135
     
89,532
 
Other assets
   
147,721
     
138,082
 
Total assets
 
$
1,950,099
   
$
1,957,076
 
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY
               
Current liabilities:
               
Accounts payable
 
$
67,083
   
$
66,174
 
Accrued expenses
   
404,493
     
446,682
 
Current portion of long-term debt
   
90,000
     
30,000
 
Total current liabilities
   
561,576
     
542,856
 
                 
Operating lease liabilities
   
108,237
     
112,275
 
Long-term debt
   
298,120
     
305,393
 
Other liabilities
   
110,692
     
102,281
 
Total liabilities
   
1,078,625
     
1,062,805
 
                 
Commitments and contingencies
               
                 
Stockholders’ equity:
               
Class A common stock – 500 million shares authorized, $0.001 par value, 90.6 million shares issued
   
91
     
91
 
Additional paid-in capital
   
579,204
     
579,801
 
Treasury stock, at cost – 40.4 million and 39.7 million shares
   
(1,505,076
)
   
(1,461,593
)
Accumulated other comprehensive loss
   
(71,626
)
   
(64,768
)
Retained earnings
   
1,868,881
     
1,840,740
 
Total stockholders’ equity
   
871,474
     
894,271
 
Total liabilities and stockholders’ equity
 
$
1,950,099
   
$
1,957,076
 

# # #
CONTACTS:
Media: media@nuskin.com, (801) 345-6397
Investors: investorrelations@nuskin.com, (801) 345-3577